Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 13.96B 12.24B 11.3B 10.44B 19.8B 1,337B 20.19B 136B 52.8B 654B 52.42B 51.27B 2,270B P/E 2026 *
-23.5x
P/E 2027 * -66.9x
Enterprise Value 13.71B 12.02B 11.1B 10.26B 19.44B 1,312B 19.83B 133B 51.84B 642B 51.47B 50.34B 2,229B EV / Sales 2026 *
15.3x
EV / Sales 2027 * 9.23x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day-2.17%
1 week+6.65%
Current month+6.52%
1 month+14.85%
3 months+12.64%
6 months+3.58%
Current year+6.76%
1 week 81.19
Extreme 81.19
86.74
1 month 72.3
Extreme 72.3
86.74
Current year 68.9
Extreme 68.9
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.9
Extreme 23.9
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Director

42,224 0.0255%
06-30Free

Chairman

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%+6.65%+104.31%+102.15% 13.96B
+0.26%+1.84%+2.20%+8.78% 49.42B
-0.36%+1.21%+420.77%+619.10% 40.34B
-2.13%+0.29%+23.91%-6.01% 34.01B
-2.29%+3.83%+23.48%+59.26% 33.56B
-0.79%+1.32%+5.78%+36.42% 26.84B
+3.82%+3.51% - - 17.22B
-2.62%-2.13%+64.96%+125.87% 15.19B
-0.69%-3.67%+11.56%+16.97% 13.36B
-1.93%-5.47%+9.16%-30.02% 12.68B
Average -0.89%+0.78%+74.01%+103.61% 25.66B
Weighted average by Cap. -0.82%+1.19%+90.05%+131.00%

Financials

2026 *2027 *
Net sales 893M 783M 723M 668M 1.27B 85.53B 1.29B 8.7B 3.38B 41.85B 3.35B 3.28B 145B 1.5B 1.32B 1.22B 1.12B 2.13B 144B 2.17B 14.62B 5.68B 70.39B 5.64B 5.52B 244B
Net income -595M -522M -482M -446M -844M -57.01B -861M -5.8B -2.25B -27.9B -2.24B -2.19B -96.85B -199M -174M -161M -149M -282M -19.01B -287M -1.93B -751M -9.3B -746M -729M -32.3B
Net Debt -252M -221M -204M -189M -358M -24.18B -365M -2.46B -955M -11.83B -948M -927M -41.07B -88.41M -77.54M -71.59M -66.15M -125M -8.46B -128M -861M -334M -4.14B -332M -325M -14.38B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-08 US$84.46 -2.17% 2,280,833
26-07-07 US$86.33 +3.79% 2,646,707
26-07-06 US$83.18 +1.69% 1,847,437
26-07-02 US$81.80 +3.30% 2,301,899
26-07-01 US$79.19 -0.13% 1,442,398
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
84.46USD
Average target price
104.86USD
Spread / Average Target
+24.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock